Tian V Tian
Overview
Explore the profile of Tian V Tian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oyon D, Lopez-Pascual A, Castello-Uribe B, Uriarte I, Orsi G, Llorente S, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):13.
PMID: 39810240
Background: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with limited treatment options and a poor prognosis. The critical role of epigenetic alterations such as changes in DNA methylation,...
2.
Gonzalez-Medina A, Vila-Casadesus M, Gomez-Rey M, Fabregat-Franco C, Sierra A, Tian T, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4491-4504.
PMID: 39078735
Purpose: FGFR2 fusions occur in 10% to 15% of patients with intrahepatic cholangiocarcinoma (iCCA), potentially benefiting from FGFR inhibitors (FGFRi). We aimed to assess the feasibility of detecting FGFR2 fusions...
3.
Luk I, Bridgwater C, Yu A, Boila L, Yanez-Bartolome M, Lampano A, et al.
Sci Transl Med
. 2024 May;
16(747):eadj7685.
PMID: 38748774
Intrahepatic cholangiocarcinoma (ICC) is an aggressive bile duct malignancy that frequently exhibits isocitrate dehydrogenase () mutations. Mutant IDH (IDHm) ICC is dependent on SRC kinase for growth and survival and...
4.
Yanez-Bartolome M, Serra-Camprubi Q, Arenas E, Escorihuela M, Castet F, Fabregat-Franco C, et al.
Methods Mol Biol
. 2024 Apr;
2806:139-151.
PMID: 38676801
Cholangiocarcinoma (CCA) poses a substantial clinical hurdle as it is often detected at advanced metastatic stages with limited therapeutic options. To enhance our understanding of advanced CCA, it is imperative...
5.
Serra-Bardenys G, Blanco E, Escudero-Iriarte C, Serra-Camprubi Q, Querol J, Pascual-Reguant L, et al.
FEBS J
. 2024 Mar;
291(11):2423-2448.
PMID: 38451841
Oxidation of histone H3 at lysine 4 (H3K4ox) is catalyzed by lysyl oxidase homolog 2 (LOXL2). This histone modification is enriched in heterochromatin in triple-negative breast cancer (TNBC) cells and...
6.
Yanez-Bartolome M, Macarulla T, Tian T
Cell Rep Med
. 2023 Nov;
4(11):101294.
PMID: 37992681
Chemotherapy resistance in biliary tract cancer (BTC) presents a major clinical hurdle. Ren et al. developed and characterized an extensive collection of BTC patient-derived organoid (PDO) models, enabling advanced investigation...
7.
Pascual-Reguant L, Serra-Camprubi Q, Datta D, Cianferoni D, Kourtis S, Ganez-Zapater A, et al.
EMBO Mol Med
. 2023 Nov;
15(12):e18459.
PMID: 37937685
Triple-negative breast cancer (TNBC) often develops resistance to single-agent treatment, which can be circumvented using targeted combinatorial approaches. Here, we demonstrate that the simultaneous inhibition of LOXL2 and BRD4 synergistically...
8.
Turpin A, Delliaux C, Parent P, Chevalier H, Escudero-Iriarte C, Bonardi F, et al.
Br J Cancer
. 2023 Oct;
129(12):1903-1914.
PMID: 37875732
Background: Neuroendocrine prostate cancer (NEPC) is an aggressive form of prostate cancer, arising from resistance to androgen-deprivation therapies. However, the molecular mechanisms associated with NEPC development and invasiveness are still...
9.
Castet F, Fabregat-Franco C, Castillo G, Navarro V, Sierra A, Acosta D, et al.
Eur J Cancer
. 2023 Oct;
194:113338.
PMID: 37793216
Background: The incidence of early-onset pancreatic cancer (EOPC) has risen dramatically in recent years. We aimed to characterise the clinical and genomic features of EOPC and evaluate their therapeutic implications....
10.
Torcal Garcia G, Kowenz-Leutz E, Tian T, Klonizakis A, Lerner J, de Andres-Aguayo L, et al.
Elife
. 2023 Jun;
12.
PMID: 37365888
Here, we describe how the speed of C/EBPα-induced B cell to macrophage transdifferentiation (BMT) can be regulated, using both mouse and human models. The identification of a mutant of C/EBPα...